Jim Cramer Names Medline (MDLN) a Sleeper Compounder

Jim Cramer Names Medline (MDLN) a Sleeper Compounder

Syeda Seirut Javed

Thu, September 10, 2026 at 4:10 PM GMT+3 4 min read

• MDLN -1.85%

During the September 8 episode of Mad Money, Jim Cramer compared Medline Inc. (NASDAQ:MDLN) to Arizona Cardinals rookie running back Jeremiyah Love and highlighted how temporary setbacks create a unique entry window for patient investors. He remarked:

For my third running back, let's bring in some new blood, please. I'm bringing in Medline, the largest IPO of 2025. This is a distributor of medical-surgical products. I know it sounds like Becton, Dickinson. It's a growing business, selling its home medical devices, consumables. Came public last December. After a hot start, it's cooled off significantly, pulling back from a high of 50 in February to the mid-30s now, only slightly above where it came public. But for those who have patience, I think Medline could be a long-term compounder. It's a real sleeper.

Hey, NFL analog, how about the Arizona Cardinals rookie running back Jeremiyah Love, the third overall pick in April's NFL draft? Beyond both being new, I think the analogy holds because both Medline and Love have temporary question marks. Medline's well off its highs in part thanks to a warehouse fire in June. Love has a great track record at Notre Dame, but now he's got an ankle injury. I think these are temporary issues for both. Sometimes, it's best to go off the beaten path. Adam Schefter would love Medline.

A Fresh IPO and a Sleeper Compounder

Cramer's mention of Medline Inc. (NASDAQ:MDLN) brings a fresh face to the portfolio lineup. As the largest public market debut of late 2025, raising nearly $6.3 billion, the company has quickly established its massive scale as a premier distributor of medical-surgical products, consumables, and home medical devices. The company's core financials back up its growth profile. Medline reported $7.7 billion in second-quarter net sales, an 11.6% year-over-year increase. Furthermore, 2026 adjusted EBITDA increased 13.4% to $1.06 billion, compared to $935 million in the second quarter of 2025, driven by higher net sales and net IEEPA tariff refund benefits. The management raised its full-year organic sales growth outlook to 9.0% to 10.0% while slightly reducing its adjusted EBITDA outlook to $3.3 billion to $3.4 billion to account for higher-than-expected inflationary pressure, remediation efforts, and retail channel softness.

Following an initial market surge after its December public debut that pushed Medline shares to a high near $50, the stock has experienced a cooling-off period, pulling back into the mid-30s. For patient long-term investors willing to look past near-term noise, the valuation compression (21x forward earnings) could offer a compelling entry point for a durable compounder.

Operational Hurdles and Supply Chain Pressures

Investing in a newly public enterprise always comes with unique execution challenges. For Medline Inc. (NASDAQ:MDLN), recent price softness has been compounded by temporary headwinds, most notably a facility warehouse fire that disrupted logistics and distribution networks. Additionally, supply chain bottlenecks and rising operating costs can put short-term pressure on profit margins and create unsteady trading sentiment for retail investors.

Hedge Fund Ownership and Market Sentiment

According to Insider Monkey's data, 52 hedge funds held a stake in Medline Inc. (NASDAQ:MDLN) during Q2, compared to 65 in the prior quarter, while short interest stands at 8.59%. This sequential dip in fund backing, paired with the current short position, may suggest that some professional managers are adopting a wait-and-see approach as the newly public distributor works through its early growing pains.

Medline Inc. (NASDAQ:MDLN) represents the type of overlooked, off-the-beaten-path opportunity that rewards long-term discipline. While it requires patience to navigate its post-IPO growing pains, its role in healthcare infrastructure makes it an intriguing addition to a diversified growth strategy.

While we acknowledge the potential of MDLN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Jim Cramer Prefers CoreWeave (CRWV) Over IREN (IREN) and Jim Cramer on Alphabet (GOOGL): "I Don't Care Where It Went, I Care Where It's Going".

Disclosure: None. Follow Insider Monkey on Google News.